USA flag logo/image

An Official Website of the United States Government

Enhanced Fluoropolymer Membrane Reactors for Production of Pharmaceutical…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43RR032260
Solicitation Year:
2011
Solicitation Topic Code:
NCRR
Solicitation Number:
PA10-122
Small Business Information
Compact Membrane Systems, Inc.
335 Water Street Newport, DE 19804-2410
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Enhanced Fluoropolymer Membrane Reactors for Production of Pharmaceutical Interme
Agency: HHS
Contract: 1R43RR032260-01
Award Amount: $396,124.00
 

Abstract:

DESCRIPTION (provided by applicant): The commercial syntheses of many pharmaceutical active ingredients and intermediates require acid catalysts and the removal of water to drive reactions to completion. Typical reactions include esterifications of carboxylic acids with alcohols, Friedel-Crafts acylations and alkylations, Schiff base, acetal and ketal formation and nitrations of aromatic compounds. Although common mineral acids are typically employed as catalysts, they create issues with product purification, waste disposal, safety, the environment and homeland security. Compact Membrane Systems, Inc. (CMS) proposes to develop membrane reactors (MR) to enhance these processes and eliminate the problems created by existing acid catalysts. CMS proposes developing enhanced membrane reactors and demonstrating performance on relevant pharmaceutical reactants. CMS has obtained key industry experts to facilitate this program. In this program, CMS will fabricate the membrane reactors. The resultant MR will be used torun reactions of pharmaceutical interest such as the alkylation and nitration of aromatic compounds. Expectation is that the CMS membrane reactor will result in higher yields, faster reactions and less contaminated products relative to incumbent processesand will have a very long lifetime due to the perfluorinated nature of the polymer. Society will benefit due to the lower production costs for the products, option for synthesis at lower temperature to maximize API efficacy, minimization of waste productsand elimination of the transport and storage of strong mineral acids. PUBLIC HEALTH RELEVANCE: Project Narrative The use of catalytic membrane reactors can replace acid catalysts in the synthesis of pharmaceutical products at lower cost and higherprocessing throughput.

Principal Investigator:

Andrew Feiring
302-999-7996
afeiring@compactmembrane.com

Business Contact:

Stuart Nemser
302-999-7996
bkelley@compactmembrane.com
Small Business Information at Submission:

COMPACT MEMBRANE SYSTEMS, INC.
335 WATER STREET NEWPORT, DE 19804-

EIN/Tax ID: 151034825
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No